This review highlights the role of blood coagulation and fibrinolysis in the pathobiology of aortic valve stenosis, specifically their interaction with inflammation and calcification.
Answers are grounded in this paper and cite their sources.
No clinical data available; leaves open coagulation-fibrinolysis interactions with inflammation and calcification in aortic stenosis.
Aortic valve stenosis (AS) increasingly afflicts our aging population. However, the pathobiology of the disease is still poorly understood and there is no effective pharmacotherapy for treating those at risk for clinical progression. The progression of AS involves complex inflammatory and fibroproliferative processes that resemble to some extent atherosclerosis. Accumulating evidence indicates that several coagulation proteins and its inhibitors, including tissue factor, tissue factor pathway inhibitor, prothrombin, factor XIII, von Willebrand factor, display increased expression within aortic stenotic valves, predominantly on macrophages and myofibroblasts around calcified areas. Systemic impaired fibrinolysis, along with increased plasma and valvular expression of plasminogen activator inhibitor-1, has also been observed in patients with AS in association with the severity of the disease. There is an extensive cross-talk between inflammation and coagulation in stenotic valve tissue which contributes to the calcification and mineralisation of the aortic valve leaflets. This review summarises the available data on blood coagulation and fibrinolysis in AS with the emphasis on their interactions with inflammation and calcification.
No takes yet. Share an insight, caveat, or question.
Natorska et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: